Report Highlights

• Country: United States
• Market: Digital Wound Measurement Devices
• Market Size 2024: USD 486.2 million
• Market Size 2032: USD 1,095.0 million
• CAGR: 10.7%
• Base Year: 2025
• Forecast Period: 2026-2032

Digital Wound Measurement in the U.S.: Market Overview

The U.S. digital wound measurement devices market was valued at USD 486.2 million in 2024 and is projected to reach USD 1,095.0 million by 2032. Hardware includes 3D structured-light scanners, digital planimetry cameras and fluorescence imaging systems, alongside software that converts images into area, depth and volume readings. Government shaped this form first: the Food and Drug Administration cleared early devices through the 510(k) pathway under the Federal Food, Drug, and Cosmetic Act, and CMS payment rules then made documented measurement a billing requirement.

The private sector has led commercialisation. Smith+Nephew, ConvaTec and Mölnlycke Health Care bundle imaging with dressings and distribute through group purchasing organisations, while venture-backed firms such as MolecuLight and Swift Medical sell directly to wound centres. Government's role has been demand-side rather than ownership: the Department of Veterans Affairs buys through the VA National Acquisition Center's Federal Supply Schedule, making the VA a price-setting institutional buyer.

Policy-Driven Growth in the U.S. Digital Wound Measurement Market

The Consolidated Appropriations Act, 2023 (Public Law 117-328) inserted Section 524B into the FD&C Act, requiring cybersecurity plans for connected devices. This raised barriers for legacy imaging tools and pushed buyers toward certified platforms, lifting demand for cloud-connected measurement systems. Manufacturers that certify under the new requirements gain procurement eligibility within hospital IT security reviews, converting compliance spending into replacement cycles.

Medicare's Physician Fee Schedule, administered by the Centers for Medicare & Medicaid Services, pays for chronic wound care through evaluation and management services and, from CY2025, short-duration remote monitoring code 99445 for 2 to 15 days of data capture. Local Coverage Determinations issued by Medicare Administrative Contractors require documented wound measurements at baseline and serial intervals for negative pressure wound therapy. Each billable episode therefore generates a measurement record, converting clinical documentation rules into recurring demand for measurement devices.

Regulatory Barriers and Compliance Costs

FDA premarket review is the first barrier. Most digital measurement software is classified as Class II and requires 510(k) clearance, with FDA's performance goal of 90 FDA days for most decisions. Clinical validation studies, which vendors fund to support area and volume accuracy claims, commonly exceed USD 250,000 according to industry estimates. Imaging hardware making depth or volume claims can require De Novo classification under Section 513(f)(2), extending timelines beyond a year.

Data governance adds a second layer of cost. The HIPAA Security Rule at 45 CFR Parts 160 and 164, enforced by the HHS Office for Civil Rights, requires encryption, access logs and business associate agreements for stored wound images. HHS proposed in December 2024 to make encryption and multi-factor authentication mandatory, a change HHS estimates will raise compliance costs for smaller vendors. Pricing is further constrained by DMEPOS competitive bidding under Section 1847 of the Social Security Act.

Policy-Created Opportunities in U.S. Wound Measurement

The Department of Veterans Affairs buys through the VA National Acquisition Center under the Federal Supply Schedule, giving listed vendors a standing channel into more than 170 VA medical centres without facility-by-facility tenders. Wound care is a priority in VA spending because diabetic foot ulcers and pressure injuries drive high-cost inpatient care among veterans. Vendors holding Federal Supply Schedule listings for imaging systems, software subscriptions and handheld capture devices gain direct access to this demand.

Remote patient monitoring reimbursement creates a home-based opportunity. Code 99445 pays for short-duration monitoring, so home health and mobile wound-care providers can deploy FDA-cleared handheld imaging with patient-captured images reviewed by clinicians. FDA Breakthrough Devices designation under Section 515B of the FD&C Act also gives novel 3D depth-measurement systems priority interaction with FDA during development.

Market at a Glance

Leading Market Participants

• ARANZ Medical
• Swift Medical
• MolecuLight
• Smith+Nephew
• ConvaTec
• Mölnlycke Health Care
• 3M
• Medline Industries
• Canfield Scientific
• Cardinal Health

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), administered by the FDA's Center for Devices and Radiological Health. Key compliance requirements include 510(k) premarket notification, Section 524B cybersecurity plans for connected devices, and registration and listing under 21 CFR Part 807. The Quality Management System Regulation under 21 CFR Part 820 takes effect on February 2, 2026, replacing the Quality System Regulation with ISO 13485:2016 alignment. Amendments to the HIPAA Security Rule proposed in December 2024 are expected to be finalised during the forecast period.

Compared with regional peers, the U.S. framework is faster but more fragmented. FDA's MDUFA V performance goals target a 90-FDA-day review for most 510(k) decisions, whereas the EU Medical Device Regulation (Regulation (EU) 2017/745) requires notified body review, with transition deadlines extended to 2027 and 2028 under Regulation (EU) 2023/607. Canada's Medical Devices Regulations (SOR/98-282) and Japan's PMDA pathways sit between these models. Reimbursement, however, is set by state Medicaid rules and by individual Medicare Administrative Contractors, which creates coverage variation that the EU and Canada do not face at the same scale.

Long-Term Policy Outlook for U.S. Digital Wound Measurement

CMS is expected to expand short-duration remote monitoring coverage in the CY2027 Physician Fee Schedule proposed rule, scheduled for publication in mid-2026. Continued use of these codes will shift the market toward home-based and mobile measurement, where smartphone-compatible FDA-cleared systems hold cost advantages over fixed 3D scanners. Policy direction favours serial, auditable data over single-point assessment, so vendors with longitudinal wound-tracking software will capture reimbursement-linked revenue through 2032.

Algorithm and software rules will reshape product design. FDA's draft guidance on AI-Enabled Device Software Functions, issued in January 2025, recommends predetermined change control plans for machine learning segmentation features. The ONC Health Data, Technology, and Interoperability rule (HTI-1, 45 CFR Part 170, effective January 2024) requires certified health IT developers to disclose decision support logic, pushing wound platforms toward FHIR-based EHR integration. By 2032, vendors without locked, validated algorithms and standards-based data exchange will face exclusion from integrated health system purchasing.